Susquehanna International Group’s Gyre Therapeutics GYRE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q4
Sell
-1,427
Closed -$44K 13419
2021
Q3
$44K Buy
+1,427
New +$47K ﹤0.01% 12384
2021
Q2
Sell
-3,227
Closed -$122K 12825
2021
Q1
$122K Buy
+3,227
New +$147K ﹤0.01% 11766
2020
Q3
Sell
-7,000
Closed -$308K 10767
2020
Q2
$308K Sell
7,000
-1,347
-16% -$63.2K ﹤0.01% 8316
2020
Q1
$274K Buy
8,347
+6,854
+459% +$315K ﹤0.01% 8154
2019
Q4
$76K Buy
+1,493
New +$62.6K ﹤0.01% 9230
2019
Q2
Sell
-6,987
Closed -$425K 10458
2019
Q1
$425K Buy
6,987
+654
+10% +$42K ﹤0.01% 6581
2018
Q4
$375K Sell
6,333
-16,840
-73% -$1.24M ﹤0.01% 6582
2018
Q3
$1.87M Sell
23,173
-3,040
-12% -$241K ﹤0.01% 4114
2018
Q2
$2.29M Buy
26,213
+2,453
+10% +$430K ﹤0.01% 3780
2018
Q1
$4.6M Buy
+23,760
New +$4.43M ﹤0.01% 2646
2017
Q2
Sell
-1,707
Closed -$121K 9420
2017
Q1
$121K Buy
+1,707
New +$99.7K ﹤0.01% 8309
2014
Q3
Sell
-165
Closed -$587K 9620
2014
Q2
$587K Buy
165
+138
+511% +$450K ﹤0.01% 7168
2014
Q1
$100K Sell
27
-187
-87% -$692K ﹤0.01% 8564
2013
Q4
$698K Buy
214
+73
+52% +$288K ﹤0.01% 6147
2013
Q3
$588K Sell
141
-172
-55% -$692K ﹤0.01% 6175
2013
Q2
$1.05M Buy
+313
New +$1.19M ﹤0.01% 4902

Other funds holding GYRE

Susquehanna International Group's GYRE Position: Q3 2025 in Review

Susquehanna International Group sold out of Gyre Therapeutics (GYRE) in Q3 2025, closing a stake of 35,912 shares — an estimated $264K sold.

Susquehanna International Group first reported a position in GYRE in Q2 2013 and held it in 25 quarters. The position peaked at $2.36M in Q1 2018. 48 funds tracked by Wall St. Rank hold GYRE as of Q3 2025.

  • Susquehanna International Group reported no remaining Gyre Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Susquehanna International Group sold 35,912 Gyre Therapeutics shares in Q3 2025, an estimated $264K.
  • Susquehanna International Group first reported a position in Gyre Therapeutics in Q2 2013 and held it in 25 quarters.
  • Susquehanna International Group's Gyre Therapeutics position peaked at $2.36M in Q1 2018.
  • 48 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q3 2025.

Based on Susquehanna International Group's 13F filing for Q3 2025, filed 14 Nov 2025.